论文信息 - 90 yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: Updated results after a median follow-up of 8.5 years from the GOTEL trial.

90 yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: Updated results after a median follow-up of 8.5 years from the GOTEL trial.

7550Background: Relapse is the main cause of therapeutic failure in follicular lymphoma (FL). We report updated long-term efficacy and toxicity results of a multicenter phase II study (GOTEL-Proven...